{
    "nctId": "NCT02896855",
    "briefTitle": "A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer",
    "officialTitle": "A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 243,
    "primaryOutcomeMeasure": "Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease that is suitable for chemotherapy\n* HER2-positive metastatic breast cancer (MBC)\n* Left ventricular ejection fraction (LVEF) greater than or equal to (\\>=) 55 percent (%) at baseline (within 42 days of randomization)\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Women of childbearing potential and men should agree to use an effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment (trastuzumab and/or pertuzumab)\n\nExclusion Criteria:\n\n* History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC)\n* History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting\n* History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (\\<) 12 months\n* History of persistent Grade \\>= 2 hematologic toxicity resulting from previous adjuvant therapy\n* Grade \\>= 3 peripheral neuropathy at randomization\n* History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or non-melanoma skin carcinoma that has been previously treated with curative intent\n* Current clinical or radiographic evidence of central nervous system (CNS) metastases\n* History of exposure to cumulative doses of anthracyclines\n* Current uncontrolled hypertension or unstable angina\n* History of congestive heart failure (CHF) of any New York Heart Association (NYHA) classification, or serious cardiac arrhythmia requiring treatment\n* History of myocardial infarction within 6 months of randomization\n* History of LVEF decrease to \\< 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy\n* Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy\n* Inadequate organ function within 28 days prior to randomization\n* Current severe, uncontrolled systemic disease\n* Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment\n* Pregnant or lactating women\n* History of receiving any investigational treatment within 28 days of randomization\n* Current known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or active hepatitis B virus (HBV)\n* Receipt of intravenous (IV) antibiotics for infection within 14 days of randomization\n* Current chronic daily treatment with corticosteroids (excluding inhaled steroids)\n* Known hypersensitivity to any of the protocol-specified study treatments\n* Concurrent participation in an interventional or noninterventional study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}